About AP-3 complex subunit mu-2
AP-3 complex subunit mu-2 (AP3M2) is a protein
from Homo sapiens identified by UniProt accession
P53677, 418 residues long.
MolForge cross-references it against 0 known binders and
52 disease associations.
Target properties
| Protein name | AP-3 complex subunit mu-2 |
| UniProt accession | P53677 |
| Gene | AP3M2 |
| Organism | Homo sapiens |
| Length | 418 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (52)
Diseases linked to this target (Open Targets).
- hair color · score 0.18
- skin pigmentation · score 0.16
- blood protein measurement · score 0.13
- juvenile myoclonic epilepsy · score 0.06
- Generalized epilepsy with febrile seizures-plus · score 0.06
- generalised epilepsy · score 0.06
- developmental and epileptic encephalopathy 94 · score 0.05
- Jeavons syndrome · score 0.05
- developmental and epileptic encephalopathy, 9 · score 0.04
- developmental and epileptic encephalopathy, 19 · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P53677-F1 | alphafold | PREDICTED | 92.79 | — |
Amino-acid sequence (418 residues)
MIHSLFLINS SGDIFLEKHW KSVVSRSVCD YFFEAQERAT EAENVPPVIP TPHHYLLSVY RHKIFFVAVI QTEVPPLFVI EFLHRVVDTF QDYFGVCSEP VIKDNVVVVY EVLEEMLDNG FPLATESNIL KELIKPPTIL RTVVNTITGS TNVGDQLPTG QLSVVPWRRT GVKYTNNEAY FDVIEEIDAI IDKSGSTITA EIQGVIDACV KLTGMPDLTL SFMNPRLLDD VSFHPCVRFK RWESERILSF IPPDGNFRLL SYHVSAQNLV AIPVYVKHNI SFRDSSSLGR FEITVGPKQT MGKTIEGVTV TSQMPKGVLN MSLTPSQGTH TFDPVTKMLS WDVGKINPQK LPSLKGTMSL QAGASKPDEN PTINLQFKIQ QLAISGLKVN RLDMYGEKYK PFKGIKYMTK AGKFQVRT
Explore AP-3 complex subunit mu-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets